[{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"EyeD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"EyeD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyeD Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EyeD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EyeD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"EyeD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyeD Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EyeD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA Northern California Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA Northern California Health Care System","highestDevelopmentStatusID":"10","companyTruncated":"VA Office of Research and Development \/ VA Northern California Health Care System"},{"orgOrder":0,"company":"Credit Valley EyeCare","sponsor":"Canadian Glaucoma Clinical Research Council","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Credit Valley EyeCare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Credit Valley EyeCare \/ Canadian Glaucoma Clinical Research Council","highestDevelopmentStatusID":"11","companyTruncated":"Credit Valley EyeCare \/ Canadian Glaucoma Clinical Research Council"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Auson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Auson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Auson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Auson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Auson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Auson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Auson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Auson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Auson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Auson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Auson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Auson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rady Children's Hospital, San Diego","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rady Children's Hospital, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rady Children's Hospital, San Diego \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Rady Children's Hospital, San Diego \/ Bausch Health"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"University of California, San Francisco | The Hospital for Sick Children | University of Toronto | Sunnybrook Health Sciences Centre | Toronto Metropolitan University | National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Drops","sponsorNew":"Unity Health Toronto \/ University of California, San Francisco | The Hospital for Sick Children | University of Toronto | Sunnybrook Health Sciences Centre | Toronto Metropolitan University | National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"7","companyTruncated":"Unity Health Toronto \/ University of California, San Francisco | The Hospital for Sick Children | University of Toronto | Sunnybrook Health Sciences Centre | Toronto Metropolitan University | National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Fraser Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Fraser Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraser Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fraser Health \/ Undisclosed"},{"orgOrder":0,"company":"Wills Eye Hospital","sponsor":"Optovue","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Wills Eye Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wills Eye Hospital \/ Optovue","highestDevelopmentStatusID":"11","companyTruncated":"Wills Eye Hospital \/ Optovue"},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amring Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amring Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amring Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"||Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ripasudil","moa":"||Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed"},{"orgOrder":0,"company":"The Emmes Company, LLC","sponsor":"Kanecia Obie Zimmerman","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"The Emmes Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"The Emmes Company, LLC \/ Kanecia Obie Zimmerman","highestDevelopmentStatusID":"8","companyTruncated":"The Emmes Company, LLC \/ Kanecia Obie Zimmerman"}]
Find Clinical Drug Pipeline Developments & Deals for Timolol Maleate
Details :
Timolol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Glaucoma.
Details :
Ripasudil-Timolol combination therapy is approved by the DCGI for glaucoma treatment in India and Akums becoming reportedly the first Indian CDMO to receive approval for this formulation.
Details :
Timolol Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Timolol Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Timolol Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hemangioma.
Details :
Combigan-Generic (brimonidine tartrate/timolol maleate) is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP.
Details :
Timolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glaucoma, Open-Angle.
Details :
STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Details :
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for treatment of elevated intraocular pressure in patients with ocular hyp...
Details :
Brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% is an alpha-adrenergic receptor agonist with a betaadrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with ocular hypertensi...
Product Name : Brimonidine Tartarate/Timolol Maleate-Generic
Reset All
